Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data demonstrating that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
The data showed a significant reduction in epileptiform activity, suggesting that KIO-300 may have potential as a therapeutic agent for epilepsy. This is particularly notable as temporal lobe epilepsy is one of the most common forms of epilepsy and is often resistant to current treatments. KIO-300 is the active pharmaceutical ingredient of KIO-301, which is currently in Kiora's ongoing Phase 2 clinical program for vision restoration in patients with gene mutation-agnostic retinitis pigmentosa.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. The company's pipeline includes KIO-301, a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration, and KIO-104, a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for the treatment of macular edema due to retinal inflammation.
The announcement of KIO-300's efficacy in a preclinical epilepsy model highlights the potential for expanding the therapeutic applications of Kiora's ion channel modulator platform beyond retinal diseases. The company plans to continue exploring the potential of KIO-300 and other ion channel modulators for neurological conditions.
For more information, visit Kiora Pharmaceuticals' website at www.kiorapharma.com.
